Trial Profile
Clinical Pharmacological Study of FYU-981 Administered to Hyperuricemic Outpatients With or Without Gout
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Jan 2024
Price :
$35
*
At a glance
- Drugs Dotinurad (Primary)
- Indications Hyperuricaemia
- Focus Pharmacodynamics; Registrational
- Sponsors Mochida Pharmaceutical
- 01 Jan 2024 A Post hoc analysis based on the data from this and NCT02837198 studies, published in the Clinical Pharmacology in Drug Development
- 21 Sep 2018 Status changed from recruiting to completed.
- 23 Jan 2018 Status changed from not yet recruiting to recruiting.